Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. In vitro methylation assays of MED12 by PRMT1/PRMT6 and correlation analyses of indicated genes in breast cancer specimens and cell lines.
  • Fig. S2. Western blotting analysis of endogenous dimethylated MED12R1862 using a methyl-specific MED12 rabbit polyclonal antibody.
  • Fig. S3. Mutation of MED12 methylation sites does not affect cell growth or EMT-associated gene expression.
  • Fig. S4. The mRNA level of CDKN1A/p21, a MED12 and CARM1 co-regulated gene, correlates with 5-FU response in vitro and predicts the probability of recurrence-free survival in breast cancer patients.
  • Fig. S5. Mutation of MED12 methylation sites does not affect the interaction of MED12 with other known interacting proteins.
  • Fig. S6. Suppression of p21 mRNA and protein levels is retained in MED12WT- but not MED12DM-expressing HEK293 cells.
  • Table S1. Primary hits from the FDA-approved oncology drug screening.

Download PDF

Other Supplementary Material for this manuscript includes the following:

  • Table S2 (Microsoft Excel format). Differentially expressed genes regulated by CARM1 and MED12.

Files in this Data Supplement: